DLK Investment Management
LAB icon

DLK Investment Management’s Standard BioTools LAB Stock Holding History

DLK Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.6K Buy
+14,380
New +$11K ﹤0.01% 98
2026
Q2 		– Sell
-11,380
Closed -$10.5K – 112
2026
Q1 		$10.5K Hold
11,380
– – ﹤0.01% 90
2025
Q4 		$14.6K Hold
11,380
– – 0.01% 88
2025
Q3 		$14.8K Hold
11,380
– – 0.01% 89
2025
Q2 		$13.7K Buy
+11,380
New +$12.6K 0.01% 88

Other funds holding LAB

Hollow Brook Wealth Management
Hollow Brook Wealth Management Katonah, New York $575M AUM 19.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
STALEY CAPITAL ADVISERS
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.67B AUM 20.47% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

DLK Investment Management's LAB Position: Q3 2026 in Review

DLK Investment Management opened a new position in Standard BioTools (LAB) in Q3 2026: 14,380 shares worth $10.6K. The stake represents ﹤0.01% of the portfolio and ranks #98 among its holdings. This is a return to the name: DLK Investment Management previously reported a position in LAB as recently as Q1 2026.

DLK Investment Management first reported a position in LAB in Q2 2025 and has held it in 5 quarters since. The position peaked at $14.8K in Q3 2025. 28 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

  • DLK Investment Management held 14,380 shares of Standard BioTools worth $10.6K as of Q3 2026.
  • Standard BioTools was a new DLK Investment Management position in Q3 2026.
  • Standard BioTools made up ﹤0.01% of DLK Investment Management's portfolio in Q3 2026, its #98 holding.
  • DLK Investment Management first reported a position in Standard BioTools in Q2 2025 and has held it in 5 quarters since.
  • DLK Investment Management's Standard BioTools position peaked at $14.8K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on DLK Investment Management's 13F filing for Q3 2026, filed 9 Oct 2026.